Main Menu

Division of Breast Cancer Research

The Division of Breast Cancer Research, which incorporates the Breast Cancer Now Research Centre, contains over 100 scientists and clinicians working in 14 teams

See Head of Division and Teams

Video: Professor Nick Turner discusses the latest results from a phase III clinical trial (Paloma-3) of the drug the findings strengthen the case for making palbociclib available to women whose cancer has progressed on prior hormone therapy.

The division is focused on identifying both the genetic and environmental causes of breast cancer, so we can improve diagnosis, assess prognosis and likely response to treatment more accurately, and discover new targets for cancer therapies.

To fulfill the aim to translate its findings rapidly to the clinic, the division has strong links with other researchers at The Institute of Cancer Research, London, clinicians at The Royal Marsden and academic and commercial collaborators.

A key priority for the division is to identify and characterise breast cancer susceptibility genes. Its researchers were responsible for one of the biggest ever discoveries in cancer genetics – the identification of the breast cancer gene BRCA2.

Its discovery has enabled families with a history of the disease to be assessed for future risk, and has helped lay the groundwork for the development of novel therapies that target BRCA-associated cancers.

One of the division’s core research programmes aims to understand how genes and the tumour microenvironment help to drive the metastasis of breast cancers to other parts of the body.

Researchers are also interested in understanding how breast cancers become resistant to treatment.They have recently discovered a mechanism by which resistance develops to aromatase inhibitors, used in the hormonal treatment of breast cancer, and are uncovering mechanisms of resistance to PARP inhibitors, developed to treat patients with germline BRCA mutations.

The Breast Cancer Now Research Centre — formerly the Breakthrough Breast Cancer Research Centre — is funded by Breast Cancer Now, and was opened in 1999 by its patron, HRH The Prince of Wales.

It houses much of the division’s research, including the Breakthrough Generations Study - the world’s largest and most comprehensive study investigating the environmental, behavioural, hormonal and genetic causes of breast cancer.

Running over the next 40–50 years, scientists are analysing up to 200 patient blood samples every day, and assessing detailed patient questionnaires, to gather unique information on over 100,000 women and identify factors influencing their breast cancer risk.

Head of Division

Professor Andrew Tutt

Professor Andrew Tutt

Director, Breast Cancer Now Toby Robins Research Centre

Andrew Tutt is Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre at the ICR and Guy’s Hospital King’s College London. He is a Clinician Scientist with the Laboratory and Clinical Trials programme, and a Consultant Clinical Oncologist looking after women with breast cancer.

020 7153 5333 ORCID 0000-0001-8715-2901

Deputy Head of Division

Professor Chris Lord

Professor Chris Lord

Professor Chris Lord is Deputy Head of Division and the leader of the CRUK Gene Function Team, which applies concepts such as synthetic lethality and non-oncogene addiction to provide one route to identifying novel approaches to treating cancer.

+44 20 7153 5190 ORCID 0000-0002-3226-0515

Research teams

Breast Cancer Clinical Research

Team leader: Dr Alistair Ring

Dr Ring’s team is working to improve the outcomes of patients with early and advanced breast cancer.

Breast Cancer Collaborations

Team leader: Professor Andrew Tutt

The Breast Cancer Collaborations Team encompasses all of the BCR positions imbedded within other teams across the ICR. These roles enable connectivity between Divisions and brings together expertise across the ICR to drive forwards progress in breast cancer research.

Breast Cancer Immunology

Team leader: Professor Alan Melcher

The Breast Cancer Immunology team is led by Alan Melcher and looks at ways to activate the immune system to attack breast cancer using therapeutic oncolytic viruses, radiotherapy, targeted drugs and combination strategies. The agents we prioritise are already in clinical use and offer major potential benefits to further improve the promising field of immunotherapy.

Breast Cancer Research Bioinformatics Group

Dr Syed Haider’s multidisciplinary team combines bioinformatics and statistical machine learning techniques to identify therapeutic vulnerabilities and biomarkers of aggressive disease, particularly in breast cancer.

Breast Cancer Systemic Therapy Trials

Team leader: Dr Alicia Okines

Dr Okine's team are investigating and conducting clinical trials on metastatic breast cancers.

Breast Surgery Outcome Measures

Team leader: Jennifer Rusby

Miss Jennifer Rusby's team develops methods for measuring breast cancer surgery outcomes. Better understanding and measurement will enable us to assess new techniques in surgery and sequencing of treatments to make improvements in patient care.

Cancer Dynamics

Team leader: Dr Stephen John Sammut

Dr Stephen John Sammut’s team is developing computational and experimental frameworks that model changes in tumour ecosystem biology during treatment to inform optimal therapy choice in the next generation of personalised precision cancer medicine trials.

Cancer Stem Cell

Team leader: Professor Axel Behrens

Professor Axel Behrens' team uses a combination of sophisticated genetics and human cancer organoids to understand the biology of cancer and to develop novel therapeutic options, with an emphasis on breast cancer and pancreatic cancer.

Cell Death and Immunity

Team leader: Professor Pascal Meier

Professor Meier and his team studies the complex relationship between cell death, inflammation and adaptive immunity, and how this knowledge might be applied to deliver better anti-cancer drugs to the clinic.

Drug Target Discovery

Team leader: Professor Andrew Tutt

The Drug Target Discovery Team is temporarily led by Professor Andrew Tutt. It was previously led by Professor Spiros Linardopoulos.

Endocrine Control Mechanisms

Team leader: Professor Cathrin Brisken

Professor Cathrin Brisken's team aims to understand how hormones drive breast cancer development to better prevent the disease and tumor recurrence.

Endocrine Therapy Resistance

Team leader: Professor Stephen Johnston

The team has researched the mechanisms of endocrine resistance, identified targets within breast cancer cells, and studied novel therapies to reverse the endocrine resistance pathways.

Functional Genetic Epidemiology

Team leader: Professor Olivia Fletcher

Professor Olivia Fletcher’s team uses intermediate phenotypes and functional studies to understand how individual genetic variants influence breast cancer risk which may, in the longer term, help to develop novel risk-reduction and prevention strategies.

Functional Genomics

Team leader: Dr Rachael Natrajan

Dr Rachel Natrajan’s Functional Genomics Team aims to identify the genetic causes of different types of breast cancer and then use this knowledge to develop new treatments for the disease.

Functional Tumour Immunology

Team leader: Dr Esther Arwert

Dr Esther Arwert’s team is identifying ways to target the tumour microenvironment to enhance anti-tumour T cell responses.

Gene Function

Team leader: Professor Chris Lord

The Gene Function Laboratory investigates the genetic basis of breast cancer as a means to understand and treat the disease.

Molecular Cell Biology

Team leader: Professor Clare Isacke

Professor Clare Isacke’s Molecular Cell Biology Team investigates the environments surrounding breast cancer cells, in order to understand the molecular basis of the disease’s progression.

Molecular Oncology

Team leader: Professor Nicholas Turner

Professor Turner’s Molecular Oncology Team is developing non-invasive analyses of breast cancer in order to identify potential therapeutic targets in cancer and track a patient’s response to treatment.

Target Validation and DNA Damage Response

Team leader: Professor Andrew Tutt

Professor Tutt’s team interests involve the discovery of novel therapies and biomarkers in BRCA1/BRCA2-associated cancers and ER/HER2-negative/basal-like breast cancers – including the identification of new drug targets and therapy combination strategies.